Skip to content
DataLookout
Menu

NCT07285694

AB-3028, a Programmable Circuit T Cell Therapy in Patients With Castration Resistant Prostate Cancer (CRPC)

StatusTerminated
PhasePhase 1/2
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 11 versions: 11 with changes below. See every version on ClinicalTrials.gov ↗

  1. Stopped Trial terminated Sponsor's reason: Sponsor decision
    • Final enrollment: 3 participants, 2% of the 190 planned
    • Eligibility criteria expanded, about 8 words
    • Primary completion date changed from estimate of May 2029 to Oct 19, 2026
  2. Minor Enrollment closed, study ongoing
    • Site details revised at 9 of 9 sites
    v10
  3. Minor Study sites: 8 to 9v9
  4. Minor Study sites: 7 to 8v8
  5. Minor Study sites: 6 to 7v7
Show 5 earlier versionsHide 5 earlier versions
  1. Minor Study sites: 4 to 6v6
  2. Minor Study sites: 3 to 4v5
  3. Minor Study sites: 2 to 3v4
  4. Minor Study sites: 1 to 2v3
  5. Notable Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    • Start date changed from estimate of Jan 2026 to Jan 9, 2026
    v2
  1. Study First Submitted
  • Stopped: terminated, suspended or withdrawn
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Safety and tolerability of AB-3028
Timeframe: From AB-3028 infusion up to 24 months post-infusion

Arms and interventions

AB-3028Experimental

Patients receive a single dose of AB-3028 intravenously on day 0.

Biologicals: AB-3028

Sites

9 sites in 1 country